Terms: = Liver cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Prognosis
58 results:
1. Comprehensive Analysis of METTLs (METTL1/13/18/21A/23/25/2A/2B/5/6/9) and Associated mRNA Risk Signature in Hepatocellular Carcinoma.
Wang H; Hu S; Nie J; Qin X; Zhang X; Wang Q; Li JZ
Anal Cell Pathol (Amst); 2023; 2023():6007431. PubMed ID: 38130905
[TBL] [Abstract] [Full Text] [Related]
2. Multi-cohort validation study of a four-gene signature for risk stratification and treatment response prediction in hepatocellular carcinoma.
Liu C; Xiao Z; Wu S; Yang Z; Ji G; Duan J; Zhou T; Cao J; Liu X; Xu F
Comput Biol Med; 2023 Dec; 167():107694. PubMed ID: 37956625
[TBL] [Abstract] [Full Text] [Related]
3. Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma.
Chong ML; Knight J; Peng G; Ji W; Chai H; Lu Y; Wu S; Li P; Hu Q
Cancer Genet; 2023 Aug; 276-277():30-35. PubMed ID: 37418972
[TBL] [Abstract] [Full Text] [Related]
4. Epithelial-mesenchymal transition-related gene prognostic index and phenotyping clusters for hepatocellular carcinoma patients.
Wang X; Zeng W; Yang L; Chang T; Zeng J
Cancer Genet; 2023 Jun; 274-275():41-50. PubMed ID: 36972656
[TBL] [Abstract] [Full Text] [Related]
5. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
[TBL] [Abstract] [Full Text] [Related]
6. Risk modeling of single-cell transcriptomes reveals the heterogeneity of immune infiltration in hepatocellular carcinoma.
Wang L; Chen Y; Chen R; Mao F; Sun Z; Liu X
J Biol Chem; 2023 Mar; 299(3):102948. PubMed ID: 36708920
[TBL] [Abstract] [Full Text] [Related]
7. Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis.
Yang Z; Liu J; Xue F; Zhang L; Xue H; Wu Y; Bai S; Du F; Wang X; Deng W; Song C; Wang K
Ann Hepatol; 2023; 28(2):100898. PubMed ID: 36634747
[TBL] [Abstract] [Full Text] [Related]
8. RNF2 mediates pulmonary fibroblasts activation and proliferation by regulating mTOR and p16-CDK4-rb1 signaling pathway.
Pan L; Hu Y; Qian C; Yao Y; Wang S; Shi W; Xu T
Inflamm Res; 2022 Nov; 71(10-11):1283-1303. PubMed ID: 35933565
[TBL] [Abstract] [Full Text] [Related]
9. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract] [Full Text] [Related]
10. ZFPM2-AS1: An Oncogenic Long Non-coding RNA in Multiple cancer Types.
Tan F
Mini Rev Med Chem; 2023; 23(1):88-98. PubMed ID: 35578882
[TBL] [Abstract] [Full Text] [Related]
11. NEK2 promotes the progression of liver cancer by resisting the cellular senescence.
Lei Q; Xia J; Feng X; Guo J; Li G; Zhou W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):153-164. PubMed ID: 35545405
[TBL] [Abstract] [Full Text] [Related]
12. 3-Mercaptopyruvate sulfurtransferase represses tumour progression and predicts prognosis in hepatocellular carcinoma.
Li M; Song X; Jin Q; Chen Y; Zhang J; Gao J; Cen L; Lin Y; Xu C; He X; Li Y; Yu C
Liver Int; 2022 May; 42(5):1173-1184. PubMed ID: 35243746
[TBL] [Abstract] [Full Text] [Related]
13. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
Thysell E; Köhn L; Semenas J; Järemo H; Freyhult E; Lundholm M; Thellenberg Karlsson C; Damber JE; Widmark A; Crnalic S; Josefsson A; Welén K; Nilsson RJA; Bergh A; Wikström P
Mol Oncol; 2022 Feb; 16(4):846-859. PubMed ID: 34889043
[TBL] [Abstract] [Full Text] [Related]
14. Pathological and genomic phenotype of second neuroendocrine carcinoma during long-term follow-up after radical radiotherapy for nasopharyngeal carcinoma.
Peng YP; Liu QD; Lin YJ; Peng SL; Wang R; Xu XW; Wei W; Zhong GH; Zhou YL; Zhang YQ; Liu Y; Wang SY; Hong HY; Liu ZG
Radiat Oncol; 2021 Oct; 16(1):198. PubMed ID: 34635145
[TBL] [Abstract] [Full Text] [Related]
15. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract] [Full Text] [Related]
16. Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based Analysis.
Wang J; Huang R; Huang Y; Chen Y; Chen F
Adv Ther; 2021 Jun; 38(6):3342-3361. PubMed ID: 34014550
[TBL] [Abstract] [Full Text] [Related]
17. Dose escalation study of targeted alpha therapy with [
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Pawlak D; Kuliński R; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3595-3605. PubMed ID: 33860346
[TBL] [Abstract] [Full Text] [Related]
18. Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma.
Song G; Zhu X; Xuan Z; Zhao L; Dong H; Chen J; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
Theranostics; 2021; 11(5):2318-2333. PubMed ID: 33500727
[TBL] [Abstract] [Full Text] [Related]
19. [Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].
Geng N; Jin YY; Zhu SX; Li YR; Zheng LY; Zhu WJ; Li YW; Han C; Dou XG; Bai H
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):861-867. PubMed ID: 33105932
[No Abstract] [Full Text] [Related]
20. Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling.
Chen L; Wang X; Cheng H; Zhang W; Liu Y; Zeng W; Yu L; Huang C; Liu G
Biochem Biophys Res Commun; 2020 Dec; 533(4):1162-1169. PubMed ID: 33039146
[TBL] [Abstract] [Full Text] [Related]
[Next]
